All-trans retinoic acid (ATRA), a target drug used for acute promyelocytic leukemia (APL), binds to the substrate binding site of Pin1 and thus inhibits Pin1 activity in breast cancer [225]. The gene discussed is PIN1; the disease is acute promyelocytic leukemia.